Novel coronavirus pneumonia is a potential effective drug, and the sea is being approved by the public.

Zhejiang Haizheng issued a notice that it received the approval of drug registration and approval of clinical trial of faveravir tablets (also known as fapiravir tablets) approved and issued by the State Drug Administration (hereinafter referred to as "the State Drug Administration") Approved for marketing in Japan in May, it is a broad-spectrum antiviral drug with indications for the treatment of new or re epidemic influenza in adults (only used when other antiviral drugs are ineffective or ineffective) In August 1999, Fushan Chemical Industry Co., Ltd applied for the first compound patent of fapiravir with a term of 20 years The company and Japan Fushan Chemical Industry Co., Ltd signed an exclusive license agreement for compound patent in June 2016 After verification, the patent for the compound expired in August 2019, and the company's R & D and production of the drug meet the relevant regulations Before that, the company did not realize commercial production of the drug After querying IMS database, no sales data of this product in domestic and foreign markets was found Up to now, the company has invested about 40.03 million yuan in the R & D project of favelaway This time, the company obtained the approval for drug registration of faveravir tablets, which is only applicable to the treatment of new or re epidemic influenza in adults According to the new indications in the approval document for clinical trials of drugs obtained this time, the clinical trials have yet to be carried out, and a series of follow-up clinical trial steps need to be submitted for review and approval There is uncertainty in the clinical trial results, and there is uncertainty in the production registration of new indications Adorable adorable